FibroGen
@kyntrabio.com
Explore the Kyntra Bio site to learn about our oncology and rare disease therapies, pipeline highlights, clinical trials, culture, and company strategy
FibroGen's Company Logos
FibroGen's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FFB81C
My Sin
255, 184, 28
41, 100, 55
0, 28, 89, 0
#04194E
Gulf Blue
4, 25, 78
223, 90, 16
95, 68, 0, 69
#FFCD2A
Sunglow
255, 205, 42
46, 100, 58
0, 20, 84, 0
About FibroGen
Kyntra Bio is at the forefront of pioneering oncology therapies that challenge the limits of what is possible in cancer treatment. The company specializes in developing innovative medications targeting life-threatening conditions, including metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and chemotherapy-induced anemia (CIA).
Their flagship product, Roxadustat, is an oral small molecule designed to stimulate red blood cell production and enhance iron transport in patients suffering from CIA. Currently, Roxadustat is in late-stage development in China, in partnership with AstraZeneca, and is approved in several countries for treating anemia associated with chronic kidney disease.
Kyntra Bio is also advancing FG-3246, a potential first-in-class antibody-drug conjugate for metastatic castration-resistant prostate cancer and other tumor types. This investigational drug is undergoing clinical trials aimed at transforming treatment paradigms while being meticulously evaluated for safety and efficacy.
With a strong emphasis on leveraging natural biological pathways, Kyntra Bio is committed to revolutionizing cancer care and improving patient outcomes.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Related Brands
Tags
Biopharmaceutical development
Oncology therapies
Rare disease therapeutics
Anemia treatments
Antibody-drug conjugates
